Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

David C. Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen Partridge; Sheila K. Pierson; Amrit Singh; Daniel J. Arenas; Jason R. Ruth; Christopher S. Nabel; Katie Stone; Mariko Okumura; Anthony P. Schwarer; Fábio Freire José; Nelson Hamerschlak; Gerald Wertheim; Michael B. Jordan; Adam D. Cohen; Vera P. Krymskaya; Arthur H. Rubenstein; Michael R. Betts; Taku Kambayashi; Frits van Rhee; Thomas S. Uldrick

doi:10.1172/jci126091

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Castleman's Awareness & Research Effort/Castleman Disease Collaborative Network, Penn Center for Precision Medicine, University Research Foundation, Intramural NIH funding, and National Heart Lung and Blood Institute.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fajgenbaum et al. (2019) studied this question.

synapsesocial.com/papers/69d9f3401ad561c673685699 https://doi.org/10.1172/jci126091

View Full Paper

Ask AI

Bookmark

Share

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

Ask about this paper

Abstract

Discussion

Cite This Study

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading